gevokizumab
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 25/100
25
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Autoimmune Inner Ear Disease
Conditions
Autoimmune Inner Ear Disease
Trial Timeline
Aug 1, 2013 → Dec 1, 2015
NCT ID
NCT01950312About gevokizumab
gevokizumab is a phase 2 stage product being developed by XOMA for Autoimmune Inner Ear Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT01950312. Target conditions include Autoimmune Inner Ear Disease.
What happened to similar drugs?
0 of 13 similar drugs in Autoimmune Inner Ear Disease were approved
Approved (0) Terminated (3) Active (10)
Hype Score Breakdown
Clinical
12
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02318914 | Phase 3 | Terminated |
| NCT01950312 | Phase 2 | Completed |
| NCT01882504 | Phase 2 | Completed |
| NCT02293564 | Pre-clinical | Completed |
Competing Products
20 competing products in Autoimmune Inner Ear Disease